Aerie launches Rhopressa in US

Aerie Pharmaceuticals announced the launch of Rhopressa in the United States for the treatment of patients with open-angle glaucoma or ocular hypertension.

Rhopressa (netarsudil ophthalmic solution 0.02%) is now available nationally and regionally through U.S. pharmaceutical distributors, with patients having access through local pharmacies, according to a company press release.

Formulary contracts for commercial insurance coverage in 2018 and Medicare Part D coverage in 2019 are being finalized. Additionally, through the availability of a co-pay savings card programs, patients covered by commercial insurance will have immediate access to the drug, Vicente Anido Jr., PhD, chairman and CEO of Aerie, said in the release.

The once-daily eye drop is designed to lower elevated IOP in patients with glaucoma or ocular hypertension. It is designed to increase the outflow of aqueous humor through the trabecular meshwork.

Rhopressa was approved by the FDA in December 2017.

Aerie Pharmaceuticals announced the launch of Rhopressa in the United States for the treatment of patients with open-angle glaucoma or ocular hypertension.

Rhopressa (netarsudil ophthalmic solution 0.02%) is now available nationally and regionally through U.S. pharmaceutical distributors, with patients having access through local pharmacies, according to a company press release.

Formulary contracts for commercial insurance coverage in 2018 and Medicare Part D coverage in 2019 are being finalized. Additionally, through the availability of a co-pay savings card programs, patients covered by commercial insurance will have immediate access to the drug, Vicente Anido Jr., PhD, chairman and CEO of Aerie, said in the release.

The once-daily eye drop is designed to lower elevated IOP in patients with glaucoma or ocular hypertension. It is designed to increase the outflow of aqueous humor through the trabecular meshwork.

Rhopressa was approved by the FDA in December 2017.